FITC-Compatible Human CD19 on Tris-Bis PAGE under reduced condition. The purity is greater than 95%.
The purity of FITC-Compatible Human CD19 is greater than 95% as determined by SEC-HPLC.
Use 100 μL FITC-Compatible Human CD19 (10 μg/mL) to detect the positive rate of 1×106 anti-CD19 CAR cells and FITC-labeled irrelevant protein (100 μL, 10 μg/mL) was served as a negative control.
CD19 is a B-lineage-specific transmembrane glycoprotein, the expression of which is maintained on more than 95% B-cell malignancies. This strict lineage restriction makes CD19 an ideal target for immune therapies using chimeric antigen receptors (CARs). T cells engineered to express a chimeric antigen receptor (CAR) against CD19 have recently been FDA approved for the treatment of relapsed or refractory large B-cell lymphoma. Despite the success and curative potential of CD19 CAR T cells, several reports describing disease relapse due to antigen loss are now emerging.
